scholarly journals Targeted Therapy in Leukaemia, Lymphoma and Myeloma

2022 ◽  
Vol 12 (1) ◽  
pp. 74
Author(s):  
Stephen Samuel Opat
Keyword(s):  
Targeted Therapy ◽  
Cancer Therapy ◽  
Blood Diseases

Historically, most advances in cancer therapy have been pioneered by clinicians managing the blood diseases [...]

Enzymatic activatable self-assembled peptide nanowire for targeted therapy and fluorescence imaging of tumors

2016 ◽  
Vol 52 (18) ◽  
pp. 3631-3634 ◽  
Author(s):  
Ying Tang ◽  
Zhan Wu ◽  
Chong-Hua Zhang ◽  
Xiao-Li Zhang ◽  
Jian-Hui Jiang
Keyword(s):  
Targeted Therapy ◽  
Cancer Therapy ◽  
Fluorescence Imaging ◽  
Cytotoxic Agents ◽  
Targeted Cancer Therapy ◽  
Self Assembled

An activatable theranostic approach based on self-assembled peptide nanostructures with surface-displayed activatable cytotoxic agents for targeted cancer therapy was developed.

scholarly journals Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials

2019 ◽  
Vol 4 (1) ◽  
Author(s):  
Yuan Cheng ◽  
Cai He ◽  
Manni Wang ◽  
Xuelei Ma ◽  
Fei Mo ◽  
...  
Keyword(s):  
Dna Methylation ◽  
Clinical Trials ◽  
Targeted Therapy ◽  
Cancer Therapy ◽  
Histone Methylation ◽  
Hematological Malignancies ◽  
Therapeutic Potential ◽  
Dna Modifications ◽  
Epigenetic Regulators ◽  
Regulate Gene

AbstractEpigenetic alternations concern heritable yet reversible changes in histone or DNA modifications that regulate gene activity beyond the underlying sequence. Epigenetic dysregulation is often linked to human disease, notably cancer. With the development of various drugs targeting epigenetic regulators, epigenetic-targeted therapy has been applied in the treatment of hematological malignancies and has exhibited viable therapeutic potential for solid tumors in preclinical and clinical trials. In this review, we summarize the aberrant functions of enzymes in DNA methylation, histone acetylation and histone methylation during tumor progression and highlight the development of inhibitors of or drugs targeted at epigenetic enzymes.

Functionalization and cancer-targeting design of ruthenium complexes for precise cancer therapy

2019 ◽  
Vol 55 (67) ◽  
pp. 9904-9914 ◽  
Author(s):  
Jinggong Liu ◽  
Haoqiang Lai ◽  
Zushuang Xiong ◽  
Bolai Chen ◽  
Tianfeng Chen
Keyword(s):  
Targeted Therapy ◽  
Cancer Therapy ◽  
Photothermal Therapy ◽  
Ruthenium Complex ◽  
Ruthenium Complexes ◽  
Cancer Targeting ◽  
Bio Imaging

Herein, the functionalized Ruthenium complex applied for bio-imaging, photodynamic/photothermal therapy, precise targeted therapy and theranostics application have been discussed.

Mesenchymal Stem Cells Mediated Drug Delivery in Tumor-Targeted Therapy

2020 ◽  
Vol 17 ◽  
Author(s):  
Mengying Xie ◽  
Lei Tao ◽  
Ziqi Zhang ◽  
Wei Wang
Keyword(s):  
Drug Delivery ◽  
Stem Cells ◽  
Clinical Trials ◽  
Mesenchymal Stem Cells ◽  
Targeted Therapy ◽  
Cancer Therapy ◽  
Tumor Cells ◽  
Therapeutic Agents ◽  
Oncolytic Viruses ◽  
Tumor Tropism

: Mesenchymal stem cells (MSCs) possess unique properties that make them potential carriers for cancer therapy. MSCs have been documented to have low immunogenicity, positive safety in clinical trials, and the ability to selectively homing to inflammation and tumor sites. Thisreview aims to introduce tumor tropism mechanism and effects of MSCs on tumor cells, and give an overview of MSCs in delivering gene therapeutic agents, oncolytic viruses and chemotherapeutics, as well as the application of MSCs-derived exosomes in tumor-targeted therapy.

The importance of measuring quality of life in phase I/II trials of cancer therapy - the effects of antibody targeted therapy: part I

1997 ◽  
Vol 6 (4) ◽  
pp. 267-272 ◽  
Author(s):  
L.D HOPE-STONE ◽  
M.P. NAPIER ◽  
R.H.J. BEGENT ◽  
N. CUSHEN ◽  
D. O'MALLEY
Keyword(s):  
Quality Of Life ◽  
Targeted Therapy ◽  
Cancer Therapy ◽  
Phase I

scholarly journals Immunomodulation via Chemotherapy and Targeted Therapy: A New Paradigm in Breast Cancer Therapy?

Breast Care ◽  
2012 ◽  
Vol 7 (4) ◽  
pp. 267-272 ◽  
Author(s):  
John Stagg ◽  
Fabrice Andre ◽  
Sherene Loi
Keyword(s):  
Breast Cancer ◽  
Targeted Therapy ◽  
Cancer Therapy ◽  
New Paradigm ◽  
Breast Cancer Therapy

scholarly journals Endocrine side effects of broad-acting kinase inhibitors

2010 ◽  
Vol 17 (3) ◽  
pp. R233-R244 ◽  
Author(s):  
Maya B Lodish ◽  
Constantine A Stratakis
Keyword(s):  
Targeted Therapy ◽  
Side Effects ◽  
Glucose Metabolism ◽  
Cancer Therapy ◽  
Fetal Development ◽  
Linear Growth ◽  
Kinase Inhibitors ◽  
Mechanisms Of Action ◽  
Cellular Level ◽  
Gonadal Function

Targeted therapy in oncology consists of drugs that specifically interfere with abnormal signaling pathways that are dysregulated in cancer cells. Tyrosine kinase inhibitors (TKIs) take advantage of unique oncogenes that are activated in certain types of cancer, and also target common mechanisms of growth, invasion, metastasis, and angiogenesis. However, many kinase inhibitors for cancer therapy are somewhat nonselective, and most have additional mechanisms of action at the cellular level, which are not completely understood. The use of these agents has increased our knowledge of important side effects, of which the practicing clinician must be aware. Recently, proposed endocrine-related side effects of these agents include alterations in thyroid function, bone metabolism, linear growth, gonadal function, fetal development, and glucose metabolism, and adrenal function. This review summarizes the most recent data on the endocrine side effects of TKIs.

Fully automated, on-site isolation of cfDNA from whole blood for cancer therapy monitoring

Lab on a Chip ◽  
2018 ◽  
Vol 18 (9) ◽  
pp. 1320-1329 ◽  
Author(s):  
Chi-Ju Kim ◽  
Juhee Park ◽  
Vijaya Sunkara ◽  
Tae-Hyeong Kim ◽  
Yongjin Lee ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Cancer Therapy ◽  
Real Time ◽  
Whole Blood ◽  
Therapy Monitoring ◽  
Real Time Monitoring ◽  
Site Isolation ◽  
Mutation Status ◽  
Fully Integrated

Fully integrated lab-on-a-disc for cfDNA isolation allows real-time monitoring of tumor mutation status during targeted therapy.

Sign in / Sign up

Export Citation Format

Share Document